Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 4/20 | 0.46 |
| ▸ | TACR1 | P25103 | 4/20 | 0.46 |
| ▸ | TACR3 | P29371 | 4/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260104 | 1.00 | TACR2 (0.46) | TACR2TACR1TACR3NSD2MCHR1 | |
| SCHEMBL4257657 | 0.93 | TACR2 (0.48) | TACR2TACR1TACR3CA1CA2 | |
| SCHEMBL4262926 | 0.92 | TACR2 (0.46) | TACR2TACR1TACR3NSD2MCHR1 | |
| SCHEMBL4257621 | 0.92 | TACR2 (0.46) | TACR2TACR1TACR3NSD2MCHR1 | |
| SCHEMBL7669440 | 0.91 | TACR2 (0.47) | TACR2TACR1TACR3MCHR1CA1 | |
| SCHEMBL7673234 | 0.91 | TACR2 (0.49) | TACR2TACR1TACR3MCHR1CA1 | |
| SCHEMBL6002594 | 0.88 | TACR2 (0.48) | TACR2TACR1TACR3CA1CA2 | |
| SCHEMBL6002109 | 0.87 | TACR2 (0.59) | TACR2TACR1TACR3 | |
| SCHEMBL4256214 | 0.87 | TACR2 (0.59) | TACR2TACR1TACR3 | |
| Acetic Acid SCHEMBL7692910 | 0.85 | TACR2 (0.57) | TACR2TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069346-A1 | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases | ALBIREO AB (SE) | 2010-03-18 | — | — | US | disclosed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069346-A1 | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases | GIPR, HRH2, BDKRB2 | TACR2 5/4885TACR1 8/4885TACR3 24/4885 |
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | TACR2 19/4885TACR1 28/4885TACR3 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.